FDA Approves Merck’s RSV Drug for Infants

The antibody is the second to receive regulatory clearance.

Employees walk past a Merck sign in front of the company's building in Summit, N.J, in an undated file photograph. Kena Betancur/Getty Images

The Food and Drug Administration (FDA) has approved Merck’s drug for respiratory syncytial virus (RSV) in infants.

Regulators cleared Enflonsia, the monoclonal antibody, for newborns and infants “born during or entering their first RSV season,” the FDA said on June 9.